Rituximab Offlabel denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for rituximab offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Rituximab Claim: Step-Therapy Requirement

A step-therapy denial (sometimes called "fail-first") means BCBS requires you to try and document inadequate response to, or intolerance of, one or more less costly or more established treatments before it will approve rituximab. For off-label uses, BCBS's step-therapy requirements may specify a sequence of conventional agents that must be tried first.

Step-therapy denials are among the most frequently overturned on appeal when the clinical record is well-organized, because the required prior therapies are often already in the patient's history — they just were not clearly documented in the prior-authorization submission. Additionally, if prior therapies are medically contraindicated for your specific case, that is an independent ground for waiving the step-therapy requirement.

## Your Federal Appeal Rights

• Step-therapy exception: Many states and most BCBS plans have a step-therapy exception process. You may be entitled to an exception if you have already tried the required agents, if they are contraindicated, or if your condition is serious enough that delay for step therapy would cause harm. Request the exception criteria in writing.
• Internal appeal: Under ERISA §503 (job-based plans) you have the right to a full-and-fair review, including the right to see the exact step-therapy criteria applied.
• External review: Under ACA §2719, IRO review is available after internal appeals, typically within a four-month filing window from the final internal denial.
• Expedited option: Available for urgent clinical situations; request in writing alongside your standard appeal.

## Documentation to Gather

1. Prior-treatment history — a complete, chronological list of every agent tried for this condition: the agent name, start date, stop date, prescribed regimen (from the prescribing record), and the documented reason for discontinuation (inadequate response, adverse effect, contraindication). Dates must be specific — month and year at minimum. 2. Diagnosis confirmation — chart records confirming the diagnosis and its current severity or activity level. 3. Prescriber step-therapy waiver letter — if the required agents are contraindicated for your specific case (allergy, comorbidity, drug interaction), your physician should document each contraindication by reference to the FDA prescribing information for that agent and your specific clinical history — without asserting unverified facts. 4. Clinical severity documentation — evidence that waiting for step-therapy trials would cause harm or that disease activity justifies moving to rituximab without further delay. 5. BCBS step-therapy criteria — obtain the exact sequence required by the current policy so your appeal addresses each step in order.

## Criteria-Mapping Structure

List each required step-therapy agent from the BCBS policy in a table. For each, write one sentence citing the chart document (date and type) that establishes you tried it and why it failed or was not appropriate. Your prescriber's letter should mirror this table structure so the reviewer can confirm compliance at a glance.